GET DAILY SIGNALSAlign Technology (ALGN) Delivers Q3 Revenue Growth and EPS Beat
Key Takeaways
- Align Technology reported Q3 2026 revenue of $1.015 billion, up 1.9% year over year and slightly above the roughly $1.01 billion consensus estimate.
- Adjusted (non-GAAP) diluted earnings per share came in at $2.80, beating analyst expectations of approximately $2.78; GAAP diluted EPS was $1.90.
- Clear Aligner revenue rose 4.2% to $839.3 million, while Imaging Systems and CAD/CAM Services revenue declined 7.6% to $175.5 million.
- Non-GAAP operating margin improved to 24.4%, above guidance, even as softer discretionary dental spending weighed on demand.
- Management guided Q4 2026 revenue to a range of $1.00 billion to $1.02 billion, below the consensus of about $1.05 billion at the time.
- For more context, readers can explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages for ALGN.
- Investors seeking additional market insights can also explore Trending AI Robots for AI-driven trading ideas.
Earnings Context and Why It Matters
Align Technology, the maker of the Invisalign clear aligner system and iTero intraoral scanners, serves as a useful indicator for consumer discretionary healthcare spending. Because aligner treatment is often elective and self-funded, the company’s results provide an early signal on dental-industry demand and patient confidence. Heading into the report, analysts had noted weakening U.S. clear aligner volumes and trimmed estimates, with several firms lowering their ratings on the stock. The Q3 print therefore mattered less for top-line growth alone than for evidence that Align could defend profitability and clear aligner volumes in a softening demand environment while positioning its digital platform and scanner ecosystem for a recovery. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter of 2026, Align Technology reported total revenue of $1.015 billion, a 1.9% increase from the prior-year quarter’s $995.7 million and modestly above consensus of roughly $1.01 billion. Clear Aligner revenue grew 4.2% year over year to $839.3 million, driven by a 6.6% increase in shipments to a record 690,635 cases. Imaging Systems and CAD/CAM Services revenue fell 7.6% to $175.5 million, reflecting softer capital equipment investment.
Net income climbed to $135.0 million from $56.8 million a year earlier. GAAP diluted earnings per share reached $1.90, compared with $0.78 in Q3 2025. On an adjusted (non-GAAP) basis, diluted EPS was $2.80, slightly ahead of the consensus of about $2.78. GAAP gross margin was 68.7% and non-GAAP gross margin was 70.4%, while non-GAAP operating margin of 24.4% came in above the company’s outlook, supported by disciplined expense management and productivity gains.
For Q4 2026, management guided revenue to between $1.00 billion and $1.02 billion, below the consensus of approximately $1.05 billion, and reiterated full-year 2026 revenue of $4.11 billion to $4.13 billion. The company also expects to repurchase up to $300 million of stock in Q4.
Market Reaction and Investor Sentiment
Sentiment into the report was cautious. Analysts had spent October lowering price targets and, in some cases, downgrading the stock amid signs of soft U.S. clear aligner demand and a weaker dental economy. Align’s adjusted EPS beat and in-line revenue were offset by Q4 guidance that fell short of consensus, underscoring management’s expectation that softer discretionary healthcare spending and cautious capital equipment purchasing will persist. The mixed setup—better-than-expected profitability against a lighter forward outlook—left investors weighing resilient margins and international growth against a still-tempered near-term demand picture. From what I see, this balance is important because it highlights how the company is managing through the current environment.
Forward Outlook and Key Factors to Monitor
Align’s fourth-quarter outlook signals that the company expects the challenging demand environment to continue. Management attributed the reduced 2026 revenue expectations to two factors: a lower Systems and Services revenue outlook tied to a mix shift toward lower-priced scanners and more flexible acquisition models, and slightly lower Clear Aligner volume and average selling price (ASP) assumptions driven by product and geographic mix plus foreign exchange.
Investors should watch several signals in the coming quarters. First, clear aligner volume and ASP trends will indicate whether demand is stabilizing or still deteriorating, particularly in North America. Second, iTero scanner placements and the shift toward flexible purchasing models will shape the profitability of the Systems & Services segment. Third, margin execution remains a bright spot, and continued expense discipline will be key to protecting operating margin as revenue growth moderates.
Longer term, Align’s investments in direct 3D printing, the NXT Technology platform, and new product categories such as the Invisalign Sports Guard represent potential growth levers, while its roughly $500 million share repurchase plan for 2026 signals management confidence. A sustained recovery in discretionary dental spending remains the primary catalyst to watch. I’m watching this closely as the next few quarters unfold.
Exploring AI-Powered Research Tools
In my own research process I often turn to Tickeron’s AI Screener to quickly filter stocks by technical patterns, fundamentals, and industry trends. It helps surface ideas and monitor setups like those around ALGN without manually scanning dozens of screens. The tool has become a regular part of how I compare companies and spot potential opportunities in the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALGN in upward trend: price rose above 50-day moving average on November 02, 2026
ALGN moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 34 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ALGN as a result. In 58 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for ALGN just turned positive on October 08, 2026. Looking at past instances where ALGN's MACD turned positive, the stock continued to rise in 31 of 42 cases over the following month. The odds of a continued upward trend are 74%.
The 10-day moving average for ALGN crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +1.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGN advanced for three days, in 190 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 63 cases where ALGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
ALGN broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. ALGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.587) is normal, around the industry mean (4.877). P/E Ratio (26.712) is within average values for comparable stocks, (37.682). Projected Growth (PEG Ratio) (0.611) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.612) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of the invisalign system for treating malocclusion
Industry PharmaceuticalsOther